Danaher Co. (NYSE:DHR) Shares Sold by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 1.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,052 shares of the conglomerate’s stock after selling 89 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Danaher were worth $1,594,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mount Yale Investment Advisors LLC boosted its holdings in shares of Danaher by 43.8% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 2,641 shares of the conglomerate’s stock valued at $660,000 after acquiring an additional 805 shares during the last quarter. Frank Rimerman Advisors LLC lifted its position in Danaher by 638.3% during the second quarter. Frank Rimerman Advisors LLC now owns 16,457 shares of the conglomerate’s stock valued at $4,112,000 after purchasing an additional 14,228 shares during the period. ProShare Advisors LLC boosted its holdings in Danaher by 7.9% in the second quarter. ProShare Advisors LLC now owns 96,531 shares of the conglomerate’s stock valued at $24,118,000 after purchasing an additional 7,091 shares during the last quarter. Alaethes Wealth LLC grew its position in Danaher by 3.1% during the 2nd quarter. Alaethes Wealth LLC now owns 6,960 shares of the conglomerate’s stock worth $1,741,000 after purchasing an additional 206 shares during the period. Finally, Legacy Financial Advisors Inc. raised its stake in shares of Danaher by 5.2% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 2,585 shares of the conglomerate’s stock valued at $646,000 after buying an additional 127 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

DHR has been the topic of a number of recent research reports. Leerink Partners raised their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI decreased their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Wells Fargo & Company started coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Finally, TD Cowen upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Stock Performance

NYSE DHR opened at $272.63 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a market cap of $201.93 billion, a PE ratio of 46.21, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The stock’s 50 day simple moving average is $267.62 and its 200-day simple moving average is $257.16.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.05 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.